Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 14, 2012Organic Process Research & Development

Large-Scale Carbonyl Reductions in the Pharmaceutical Industry

View Full Paper
Ask AI
Bookmark
Share

Authors

JMJavier MaganoPfizer (United States)JDJoshua R. DunetzGilead Sciences (United States)

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Magano et al. (2012) studied this question.

synapsesocial.com/papers/69dab18ba6045d71bfa3dcfahttps://doi.org/10.1021/op2003826
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Research and Development of an Efficient Synthesis of Hexahydrofuro[2,3-b]furan-3-ol Moiety—A Key Component of the HIV Protease Inhibitor Candidates2007 · 32 citations
  2. 2A Scaleable Synthesis of Fiduxosin2004 · 52 citations
  3. 3Development of a Scaleable Synthesis of a 3-Aminopyrazinone Acetamide Thrombin Inhibitor2004 · 25 citations
  4. 4A Practical Synthesis of Renin Inhibitor MK-1597 (ACT-178882) via Catalytic Enantioselective Hydrogenation and Epimerization of Piperidine Intermediate2011 · 34 citations